This second round of funding raises the equivalent of $45.4 million to support the advancement of Oxford-based Evox’s exosome-based therapeutics pipeline, including pushing several rare disease ...

Prior to Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing ... developed a dominant IP estate and advanced the Company’s proprietary pipeline towards the clinic. “On ...

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics OXFORD, United ...

OXFORD, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted ...

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual ...

OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with ...

Partnership with Icahn School of Medicine will involve developing exoAAV vectors for heart disease patients Partnership with Icahn School of Medicine will involve developing exoAAV vectors for heart ...

About Evox Therapeutics Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular ...